In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's Fosamax [1]. D-mab, as it's known, showed greater improvement in bone mineral density in the hip and spine compared to Fosamax. "The novel means by which denosumab inhibits osteoclast-mediated bone breakdown shows the promise of RANK Ligand inhibition," said Javier San Martin, Global Development Lead for the denosumab osteoporosis program.
- see Amgen's release [2]
- read the report [3] for more
Related Articles:
Merck expects $1.8B hit on Fosamax [1]
Amgen's D-mab posts positive in late-stage trial [4]
Amgen CEO touts blockbuster potential of D-mab [5]
Denosumab: Amgen's salvation? [6]
Amgen touts progress in two key programs [7]
Links:
[1] http://www.fiercepharma.com/story/merck-expects-1-8b-hit-fosamax/2007-12-04?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FP0
[2] http://www.fiercebiotech.com/press-releases/amgen-says-denosumab-improves-bone-density-trial
[3] http://money.cnn.com/news/newsfeeds/articles/apwire/cb55a74660d0af352de208030210d5cb.htm
[4] http://www.fiercebiotech.com/story/amgen-s-d-mab-posts-positive-in-late-stage-trial/2008-04-03
[5] http://www.fiercebiotech.com/story/amgen-ceo-touts-blockbuster-potential-of-d-mab/2008-02-14
[6] http://www.fiercebiotech.com/story/denosumab-amgens-salvation/2007-12-14
[7] http://www.fiercebiotech.com/story/amgen-touts-progress-in-two-key-programs/2007-04-24